Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.56 |
| ▸ | METAP1 | P53582 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268592 | 0.93 | KDM4E (0.56) | METAP1MAOBKDM4EHTTCYP19A1 | |
| SCHEMBL29392039 | 0.93 | MAOB (0.54) | MAPK14METAP1MAOBKDM4EHTT | |
| SCHEMBL251842 | 0.93 | MAOB (0.54) | MAPK14METAP1MAOBKDM4EHTT | |
| SCHEMBL3860885 | 0.93 | MAPK14 (0.50) | MAPK14METAP1MAOBCYP19A1 | |
| Water SCHEMBL28454486 | 0.91 | KDM4E (0.54) | METAP1MAOBKDM4EHTTCYP19A1 | |
| Butane SCHEMBL4688097 | 0.87 | BRD4 (0.52) | MAPK14METAP1MAOBKDM4EHTT | |
| SCHEMBL5871789 | 0.86 | MAOB (0.58) | MAPK14METAP1MAOBCYP19A1 | |
| Acetic Acid SCHEMBL6934641 | 0.85 | MAOB (0.51) | MAPK14METAP1MAOBKDM4EHTT | |
| SCHEMBL29756894 | 0.83 | MAOA (0.58) | MAPK14METAP1MAOBKDM4EHTT | |
| SCHEMBL115638 | 0.83 | MAOA (0.58) | METAP1MAOBKDM4EHTTCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435940-A4 | TREATMENT OF SCLERODERMA | CELL PATHWAYS INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1435940-A1 | TREATMENT OF SCLERODERMA | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435782-A1 | TREATMENT FOR CYSTIC FIBROSIS | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003017765-A1 | TREATMENT FOR CYSTIC FIBROSIS | CELL PATHWAYS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003017999-A1 | TREATMENT OF SCLERODERMA | CELL PATHWAYS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |